Basic fibroblast growth factor (bFGF) is a po tent neurotrophic agent that promotes neuronal survival and outgrowth. Previous studies have shown that bFGF, administered intraventricularly or intravenously before or within hours after ischemia, reduces infarct size and neu rological deficits in models of focal cerebral ischemia in rats. In the current study, we tested the hypothesis that bFGF, administered at later time points after ischemia, might improve behavioral recovery without affecting in farct size. Mature Sprague-Dawley rats received bFGF (l /-lglinjection) or vehicle by biweekly intracisternal injec tion for 4 weeks, starting at 1 day following permanent proximal middle cerebral artery (MCA) occlusion. Ani mals were examined every other day using four different behavioral tests to assess sensorimotor and reflex func-Address correspondence and reprint requests to Dr. Seth Finklestein at CNS Growth Factor Research Laboratory, MGH East, 6th Fl., 149 13th St., Charlestown, MA 02129, U.S.A. Abbreviations used: ANOYA, analysis of variance; bFGF, ba sic fibroblast growth factor; CSF, cerebrospinal fluid; MCA, middle cerebral artery. ] Cereb Blood Flow Metab II :472-478 Yamaguchi T, Suzuki M, Yamamoto M (1995) YM796, a novel muscarinic agonist, improves the impairment of learning be havior in a rat model of chronic focal cerebral ischemia. Brain Res 669:107-114 Yamamoto M, Tamura A, Kirino T, Shimizu-Sasamata M, Sano K (1991) Effects of thyrotropin-releasing hormone on behav ioral disturbances in middle cerebral artery-occluded rats.
Although recovery from sensorimotor, cognitive, and other disabilities after stroke is often incom plete, partial recovery often occurs. Mechanisms of recovery may include reversal of metabolic sup pression in distant brain regions ("diaschisis"), un masking of normally inhibited alternative brain pathways, and neuronal sprouting and synapse for mation (Goldstein and Davis, 1990) . Recent func tional imaging studies in humans show new activa-tion. At 4 weeks after ischemia, there was no difference in infarct volume between bFGF-and vehicle-treated ani mals. There was, however, an enhancement in the rate and degree of behavioral recovery among bFGF-treated animals, as measured by all four tests. There were no apparent side effects of bFGF treatment, except that bFGF-treated animals tended to recover body weight more slowly than did vehicle-treated animals following stroke. The mechanisms of enhancement of behavioral recovery by bFGF require further study, but may include protection against retrograde neuronal death and/or stim ulation of neuronal sprouting. Key Words: Basic fibro blast growth factor-Cerebral infarction-Behavior Recovery.
tion of brain regions both ipsilateral and contralat eral to focal infarcts as patients recover motor function after stroke (Weiller et aI. , 1992) . In ani mals, new neuronal sprouting and synaptic reorga nization occur in both ipsilateral and contralateral cerebral cortex during motor recovery after unilat eral cortical lesions or infarcts (Jones and Schallert, 1994; Stroemer et aI. , 1995) .
Neurotrophic growth factors are likely to play im portant roles in the regulation of molecular and cel lular processes underlying recovery after stroke. These endogenous polypeptides, acting through high affinity receptors, initiate and sustain cellular processes supporting cell survival and outgrowth.
In particular, basic fibroblast growth factor (bFGF), an 18 kDa, 154 amino acid polypeptide, that is found in brain, supports the survival and outgrowth of a wide variety of brain neurons, as well as glial and endothelial cells (Baird, 1994) . Endogenous bFGF expression is upregulated in tissue surround ing focal brain wounds or infarcts, and exogenous application of bFGF reduces the degree of cell death and stimulates neuronal sprouting in several models of brain injury or ischemia (Berlove and Finklestein, 1993; Finklestein, 1995) . In particular, in previous studies, we showed that bFGF, admin istered intraventricularly or intravenously before or just after ischemia, reduced infarct volume and neu rological deficits in models of focal cerebral isch emia in mature rats (Koketsu et al., 1994; Fisher et al. , 1995) . The mechanisms of infarct reduction may include direct protective effects on cells at the bor ders ("penumbra") of focal infarcts and/or effects on cerebrovascular tone and cerebral blood flow. The infarct reducing effects of bFGF, however, are likely to occur within a relatively narrow "thera peutic window" of time after ischemia. Indeed, other investigators have shown that intracisternal administration of bFGF starting at 1 day after focal ischemia does not reduce infarct volume, but does protect against the "secondary" death of distant neurons projecting into infarcted regions (Yamada et al., 1991) . Because bFGF may regulate several cellular processes contributing to functional recov ery after stroke, we tested, in the current study, the hypothesis that late administration of bFGF might enhance neurological recovery without affecting in farct size after ischemia. In this study, bFGF was delivered intracisternally to gain access to intact as well as ischemic cerebral hemispheres.
METHODS
Male Sprague-Dawley rats (25(}"'300 g) (Charles River, Wilmington, MA, U.S.A.) were maintained on a 12-h light/dark cycle and allowed free access to food and wa ter. Rats were anesthetized with 2% halothane in 70% NOz/30% O2 (vol/vol). The tail artery was cannulated for monitoring blood gases and blood glucose. Body temper ature was maintained at 37 ± O.SOC using a rectal probe and heating pad. The proximal right middle cerebral ar tery (MCA) was occluded permanently using a modifica tion of the method of Tamura et a!. (1981) . Briefly, the proximal MCA was exposed transcranially without re moving the zygomatic arch or transecting the facial nerve. The artery was then electrocoagulated using a bi polar microcoagulator from just proximal to the olfactory tract to the inferior cerebral vein, and was then transected (Bederson et aI., 1986) . Rats were observed until they regained consciousness and were returned to their home cages. Cefazolin sodium (40 mg/kg, body wt i.p.) was administered on the day before and just after stroke sur gery.
Recombinant human bFGF was obtained as concen trated stock (2 mg/ml) as a generous gift from Scios Inc. (Mountain View, CA, U.S.A.), and stored at -80%C before use. Stock solution was then diluted into a solu tion containing 0.9% saline with 100 fLg/ml bovine serum albumin (Boehringer-Mannheim, Indianapolis, IN, U.S.A.), pH 7.4, to give a final bFGF concentration of 20 fLg/ml. Control animals received vehicle solutions with no bFGF, but containing all other components at the same final concentrations.
For intracisternal injections, animals were reanesthe tized with halothane in 70% N02/30% Oz (vol/vol) and placed in a stereotaxic frame. bFGF (1 J.Lg/injection, n = 14 animals) or vehicle (n = 8 animals) was introduced by percutaneous injection (50 fLlIinjection) into the cisterna magna using a Hamilton syringe and 26-gauge needle un der aseptic technique (Yamada et a!., 1991) . Before each injection, 1-2 fLl of cerebrospinal fluid (CSF) was drawn back through the Hamilton syringe to verify needle place ment in the subarachnoid space. We found in preliminary studies that dye (1 % Evans blue) delivered in this fashion diffused freely through the basal cisternae and over the cerebral cortex within 1 h of injection. Intracisternal in jections were made biweekly for 4 weeks, starting 24 h after stroke (i.e., on post stroke days 1,4,8, 11, 15, 18,22, and 25) . The total bFGF dose delivered was 8 fLg/animal. Animals were assigned to bFGF or vehicle treatment in a random fashion.
Rats were handled for 10 min each day for 3 days be fore stroke surgery. Following surgery, they were housed in individual cages. Four behavioral tests were used to assess sensorimotor and reflex function after infarction. Full details of these tests have been described elsewhere (Bederson et a!., 1986 ; DeRyck et a!., 1992; Markgraf et a!., 1992; Alexis et a!., 1995). Briefly, theforelimb placing test is comprised of three subtests. Separate scores are obtained for each forelimb. For the visual placing subtest, the animal is held upright by the examiner and brought close to a table top. Normal placing of the limb on the table is scored as 0, delayed placing «2 s) is scored as 1, and no or very delayed placing (>2 s) is scored as 2. Separate scores are obtained first as the animal is brought forward and then again as the animal is brought sideways to the table (maximum score per limb, 4; in each case, higher numbers denote greater deficits). For the tactile placing subtest, the animal is held so that it cannot see or touch the table top with its whiskers. The dorsal forepaw is touched lightly to the table top as the animal is first brought forward and then brought sideways to the table. Placing each time is scored as above (maximum score per limb, 4). For the proprioceptive placing subtest, the ani mal is brought forward only, and greater pressure is ap plied to the dorsal forepaw; placing is scored as above (maximum score per limb, 2). These subscores are added to give the total forelimb placing score per limb (range, (}"'1O). The hindlimb placing test is conducted in the same manner as above for the hindlimbs, but involves only tactile and proprioceptive subtests (maximal scores 4 and 2, respectively; total score range, (}...6 ). The modified beam balance test examines vestibulomotor reflex activ ity as the animal balances on a narrow beam (30 x 1.3 em) for 60 s. Ability to balance on the beam is scored as follows: animal balances with all four paws on the top of beam, 1; animal puts paws on side of beam or wavers on beam, 2; one or two limbs slip off beam, 3; three limbs slip off beam, 4; animal attempts to balance with paws 'on beam but falls off, 5; animal drapes over beam, then falls off, 6; animal falls off beam without an attempt to bal ance, 7. Animals received three training trials before sur-gery; the score of the last of these was taken as the base line score. The postural reflex test measures both reflex and sensorimotor function. Animals are first held by the tail suspended above the floor. Animals that reach sym metrically toward the floor with both forelimbs are scored as O. Animals showing abnormal postures (flexing of a limb, rotation of the body) are then placed on a plastic backed sheet of paper. Those animals able to resist side to-side movement with gentle lateral pressure are scored as 1, while those unable to resist such movement are scored as 2. All behavioral tests were administered just before stroke surgery and then every other day from post stroke day 1 to day 31. At each session, animals were allowed to adapt to the testing room for 30 min before testing began.
On day 31 after MCA occlusion, animals were anesthe tized deeply with pentobarbital and perfused trans car dially with heparinized saline followed by 10% buffered formalin. Brains were removed, cut into three pieces, and stored in 10% buffered formalin before dehydration and embedding in paraffin. Coronal sections (5 /-lm) were cut on a sliding microtome, mounted into glass slides, and stained with hematoxylin and eosin. The area of cerebral infarcts on each of seven slices (+ 4.7, + 2.7, + 0. 7 , -1.3 , -3 . 3, -5. 3, and -7.3 mm compared to bregma) was determined using a computer-interfaced imaging sys tem (Bioquant, R&M Biometrix, Inc., Nashville, TN, U.S.A.). Total infarct area per slice was determined by the "indirect method" as area of the intact contralateral hemisphere -area of the intact ipsilateral hemisphere, to correct for brain shrinkage during processing (Swanson et aI., 1990) . Infarct volume was then expressed as a per centage of the intact contralateral hemispheric volume. The volumes of infarction in cortex and striatum were also determined separately using these methods.
The experimenter performing intracisternal injections, behavioral testing, and histological analysis was blinded to the treatments assigned until all data had been col lected. Data were expressed as means ± SD and were analyzed by repeated measures analysis of variance (ANOV A) followed by appropriate unpaired two-tailed t-tests, with the Bonferroni correction for multiple com parisons.
RESULTS
During stroke surgery, there were no differences in blood gases or glucose among animals that were to receive bFGF or vehicle treatment. Seventeen of 22 animals prepared initially survived for 1 month after infarction, including nine of 14 bFGF-treated and all of eight vehicle-treated animals. Surviving animals were killed at day 31; these animals had large infarcts in the right lateral cerebral cortex and underlying striatum in the territory of the MeA, as has been described previously using these methods (Tamura et aI. , 1981; Bederson et aI. , 1986 ; Mark graf et aI., 1992) (see Fig. 1 ). Brain regions severely damaged by infarcts included parietal cortex, areas 1 and 2; and granular insular cortex. Regions par tially damaged by infarcts included frontal cortex, areas 1, 2, and 3; agranular insular cortex; temporal cortex, areas 1 and 3; lateral occipital cortex, area 2; cortical forelimb area; and caudoputamen (Paxi nos and Watson, 1986). The cortical hindlimb area was generally spared by infarcts. There was no dif ference in total infarct volume between bFGF-(n = 9) and vehicle-treated (n = 8) animals (31.1 ± 5.9 versus 30.0 ± 5.3% of intact contralateral hemi spheric volume, respectively, t = 0.4, p, not signif icant). Moreover, there was no difference in corti cal or striatal infarct volume among bFGF versus vehicle-treated animals when these volumes were calculated separately. Inspection of hematoxylin/ eosin stained sections showed no evidence of ab normal cell proliferation in the brains of bFGF treated animals. Following infarction, animals showed severe dis turbances of sensorimotor and reflex function on all four behavioral tests, as reported previously using these methods (Bederson et aI. , 1986; Markgraf et aI. , 1992) . For the limb placing tests, deficits were confined to the contralateral (left) limbs. As de scribed previously, animals showed partial recov ery on all four behavioral tests during the first month after stroke (Bederson et aI. , 1986; Mark graft et aI. , 1992 ) (see Figs. 2 and 3) . Moreover, bFGF-treated animals recovered more rapidly and to a greater degree than did vehicle-treated rats. Improved recovery of surviving bFGF-versus ve hicle-treated animals was most pronounced for forelimb and hindlimb placing tasks, and less pro nounced, although still significant, for beam bal ance and postural reflex tests (Figs 2 and 3) . En hanced recovery was seen on all subtests of the limb placing tests (visual, tactile, and propriocep tive) following bFGF treatment (data not shown).
Five of 14 bFGF-treated animals died from se-vere progressive weight loss during the first month after stroke. Behavioral recovery of bFGF-treated animals that died was similar to that of surviving bFGF-treated animals until the time of death at 7-23 days after stroke. The mean weight of bFGF treated animals that died was 165 ± 11 g on the day of death. Among surviving animals, there was a smaller degree of initial weight loss followed by a gradual recovery of body weight after stroke ( T. KAWAMATA ET AL. 4). Surviving bFGF-treated animals tended to re cover body weight more slowly than did vehicle treated rats (Fig. 4) .
DISCUSSION
Repeated intracisternal administration of bFGF, starting at 1 day after ischemia, enhanced behavior al recovery in a rat model of focal cerebral infarc tion. Improved behavioral recovery was seen with out a change in infarct volume in bFGF-compared to vehicle-treated animals. These data are consis tent with those of Yamada et ai. (1991) , who, using a similar model of focal infarction in rats, also found that repeated intracisternal administration of bFGF (one injection/week x 4 weeks, 1 f-lg/injection), be ginning at 1 day after ischemia, had no effect on infarct size. In previous studies (Koketsu et aI. , 1994; Fisher et aI. , 1995) , we showed that intraven tricular administration of bFGF starting before fo cal ischemia or intravenous administration of bFGF starting within the first few hours after ischemia did, indeed, reduce infarct size. Under these latter circumstances, intravenously-administered bFGF crossed the damaged blood-brain barrier and en tered the ischemic, but not the nonischemic, hemi sphere (Fisher et aI. , 1995) . In the current study, bFGF was given starting at 1 day after ischemia, beyond the apparent "therapeutic window" of time during which bFGF can reduce infarct size. More over, in the current study, bFGF was given intrac isternally in an attempt to access the nonischemic as well as the ischemic hemispheres, since cortex in the intact hemisphere appears to play an impor tant role in recovery from brain injury or stroke (Jones and Schallert, 1994; Stroemer et aI. , 1995) . To our knowledge, the current findings represent the first demonstration that an exogenously admin istered neurotrophic growth factor can enhance be havioral recovery without a reduction in infarct size in an animal model of stroke. Similar results have been reported recently for other classes of sub stances, including neurohormones and neurotrans mitter agonists (Yamamoto et aI. , 1991; Yamaguchi et aI. , 1995) . Enhancement of recovery by bFGF was most pronounced on tests of sensorimotor function of the affected limbs and less pronounced on tests of re flex and postural function. Our infarcts did not com pletely damage forelimb and hindlimb cortical ar eas, findings compatible with recovery on limb placing tests following focal infarction in the MCA territory (DeRyck et aI. , 1992; Markgraf et aI. , 1992) . Treatment with bFGF enhanced both the rate and degree of behavioral recovery during the first month after infarction. Further work will be re quired to determine whether this improvement per sists for> I month. Possible mechanisms by which bFGF enhances recovery include protection against retrograde cell death and/or acceleration of new neuronal sprouting and synapse formation. Yamada et ai. (1991) found that repeated intracisternal injec tion of bFGF protected against retrograde death of distant thalamic neurons projecting into the infarct ed cortex. This retrograde neuronal death occurs days to weeks after ischemia. It is possible that dis tant neurons in the thalamus and elsewhere, spared by bFGF treatment, might establish new functional connections, thereby enhancing recovery. Other in vestigators have reported new axonal and dendritic sprouting and synapse formation in cerebral cortex, both ipsilateral and contralateral to unilateral corti cal lesions or infarcts in rats (Jones and Schallert, 1994; Stroemer et aI. , 1995) . The time course of sprouting in the intact hemisphere parallels that of sensorimotor recovery of the affected limb, and blocking of sprouting (by splinting of the intact limb) inhibits recovery (Jones and Schallert, 1994) . As noted above, bFGF promotes neuronal out growth in vitro and stimulates axonal sprouting in models of neurotoxic brain injury in vivo (Berlove and Finklestein, 1993; Finklestein, 1995) . It is pos sible that augmentation of dendritic and/or axonal sprouting by bFGF in the poststroke brain contrib utes to enhancement of functional recovery.
Treatment with intracisternal bFGF was not without side effects. Indeed, five of 14 animals re ceiving bFGF died due to progressive weight loss, and there was a trend toward lower body weight in surviving bFGF-treated animals. These data are consistent with those previous reports showing that intracerebrally-administered bFGF lowers body weight in rats (Koketsu et aI. , 1994) . It is possible that a reduced dose or frequency of bFGF adminis tration might reduce effects on body weight without changing effects on behavioral recovery. It is un likely, however, that the improved behavioral scores we observed were simply artifacts of lower body weight since all of the behavioral tests used (except the beam balance test) were done with the examiner supporting the animal. Of additional note is that in spite of known mitogenic effects of bFGF on glial and endothelial cells, we saw no gross evi dence of abnormal cell proliferation in brains of bFGF-treated animals, although further studies us ing specific cell staining methods will be required to address this point. Indeed, further considerable study of the dose and time windows of efficacy, side effects, and molecular and cellular mechanisms of enhancement of behavioral recovery by intracister nal bFGF are required.
